Sellas Life Sciences Group Inc (SLS) has a current Price-to-Book (P/B) ratio of 11.92. Compared to its 3-year average P/B ratio of 6.23, the current P/B ratio is approximately 91.30% higher. Relative to its 5-year average P/B ratio of 6.32, the current P/B ratio is about 88.69% higher. Sellas Life Sciences Group Inc (SLS) has a Forward Free Cash Flow (FCF) yield of approximately -4.94%. Compared to its 3-year average FCF yield of -49.95%, the current FCF yield is approximately -90.11% lower. Relative to its 5-year average FCF yield of -40.46%, the current FCF yield is about -87.79% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for SLS competitors is 6.10, providing a benchmark for relative valuation. Sellas Life Sciences Group Inc Corp (SLS.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of SLS increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of SLS in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is SLS currently overvalued or undervalued?

What is Sellas Life Sciences Group Inc (SLS) fair value?

SLS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Sellas Life Sciences Group Inc (SLS) is between to according to relative valuation method.

How does SLS's valuation metrics compare to the industry average?

The average P/S ratio for SLS's competitors is 6.10, providing a benchmark for relative valuation. Sellas Life Sciences Group Inc Corp (SLS) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Sellas Life Sciences Group Inc (SLS) as of Mar 02 2026?

As of Mar 02 2026, Sellas Life Sciences Group Inc (SLS) has a P/B ratio of 11.92. This indicates that the market values SLS at 11.92 times its book value.

What is the current FCF Yield for Sellas Life Sciences Group Inc (SLS) as of Mar 02 2026?

As of Mar 02 2026, Sellas Life Sciences Group Inc (SLS) has a FCF Yield of -4.94%. This means that for every dollar of Sellas Life Sciences Group Inc's market capitalization, the company generates -4.94 cents in free cash flow.

What is the current Forward P/E ratio for Sellas Life Sciences Group Inc (SLS) as of Mar 02 2026?

As of Mar 02 2026, Sellas Life Sciences Group Inc (SLS) has a Forward P/E ratio of -16.11. This means the market is willing to pay $-16.11 for every dollar of Sellas Life Sciences Group Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Sellas Life Sciences Group Inc (SLS) as of Mar 02 2026?

As of Mar 02 2026, Sellas Life Sciences Group Inc (SLS) has a Forward P/S ratio of 0.00. This means the market is valuing SLS at $0.00 for every dollar of expected revenue over the next 12 months.

SLS Valuation